Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
Cancer Biol Ther. 2018 Feb 14;:0
Authors: Tampaki EC, Tampakis A, Droeser R, Patsouris E, Kouraklis G
PMID: 29442576 [PubMed - as supplied by publisher]
http://ift.tt/2C1meNB
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου